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INTRODUCTION
Lung cancer, as one of the most common cancers 
worldwide, has a complex disease mechanism and 
both genetic and environmental factors, as well as the 
interactions among those factors contribute to development 
of this deadly disease [1-9]. The past decade has witnessed 
the harvest of genome-wide association studies (GWAS) 
in complex disease studies and several common variants 
predisposing to lung cancer have been identified including 
TERT at 5p15, TP63 at 3q28, HLA region at 6p21, and 
CHRNB4-CHRNA3-CHRNA5 region at 15q25, etc [2-6]. 
However, the discovered genetic variants only account for 
a limited fraction of the heritability of lung cancer [10]. 
Genetic interactions, i.e., epistasis is believed to contribute 
to a considerable proportion of the missing heritability 
in complex human diseases [11-12]. Epistasis, is the 
phenomenon where the effect of one gene is dependent 
on the effects of one or more other genes that may not 
be detected solely by studying the main effect of either 
gene alone. There is growing evidence showing that 
epistasis is involved in lung cancer development [9,13-
14]. In 2014, researchers conducted a genome-wide gene-
gene interaction analysis and identified an epistasis effect 
between rs2562796 (gene: HIBCH) and rs16832404 (gene: 
c2orf88) in lung cancer development [9]. Neither of these 
two genes has been identified from main effect association 
analysis before, suggesting that genetic interactions, 
especially those among novel variants, remain unrevealed 
in lung cancer study. To date, the reports on large-scale 
genetic interaction analysis in human diseases remain 
quite limited because of the challenge in high-dimensional 
data analysis.
The development of cancer is driven by the 
accumulation of many oncogenesis-related genetic 
alterations and tumorigenesis is triggered by complex 
networks of involved genes rather than independent 
actions [15-18]. Extensive molecular studies have revealed 
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ABSTRACT
The development of cancer is driven by the accumulation of many oncogenesis-
related genetic alterations and tumorigenesis is triggered by complex networks of 
involved genes rather than independent actions. To explore the epistasis existing 
among oncogenesis-related genes in lung cancer development, we conducted pairwise 
genetic interaction analyses among 35,031 SNPs from 2027 oncogenesis-related 
genes. The genotypes from three independent genome-wide association studies 
including a total of 24,037 lung cancer patients and 20,401 healthy controls with 
Caucasian ancestry were analyzed in the study. Using a two-stage study design 
including discovery and replication studies, and stringent Bonferroni correction for 
multiple statistical analysis, we identified significant genetic interactions between 
SNPs in RGL1:RAD51B (OR=0.44, p value=3.27x10-11 in overall lung cancer and 
OR=0.41, p value=9.71x10-11 in non-small cell lung cancer), SYNE1:RNF43 (OR=0.73, p 
value=1.01x10-12 in adenocarcinoma) and FHIT:TSPAN8 (OR=1.82, p value=7.62x10-11 
in squamous cell carcinoma) in our analysis. None of these genes have been identified 
from previous main effect association studies in lung cancer. Further eQTL gene 
expression analysis in lung tissues provided information supporting the functional 
role of the identified epistasis in lung tumorigenesis. Gene set enrichment analysis 
revealed potential pathways and gene networks underlying molecular mechanisms 
in overall lung cancer as well as histology subtypes development. Our results provide 
evidence that genetic interactions between oncogenesis-related genes play an 
important role in lung tumorigenesis and epistasis analysis, combined with functional 
annotation, provides a valuable tool for uncovering functional novel susceptibility 
genes that contribute to lung cancer development by interacting with other modifier 
genes.
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interactions existing between selected cancer driver genes, 
such as cooperation of MYC and RAS in transformation 
and immortalization process, and BRCA1 and P53 in 
breast cancer development, etc [19-20]. These are only 
tips of iceberg and much more latent genetic interactions 
among cancer-related genes are waiting to be identified. 
We hypothesized that there are considerable interactions 
among oncogenesis-related genes underlying lung 
tumorigenesis and a GxG interaction association analysis 
provides us a potent tool to explore it. An epistasis study 
among oncogenesis-related genes in lung cancer will help 
us identify oncogenes or tumor suppressors affecting 
early stages of lung cancer development that cannot be 
captured by single-locus analysis; provide insights about 
the connected pathways and genetic networks involved in 
lung cancer development; and discover novel targets for 
disease treatment. And the results from interaction analysis 
can be leveraged to improve lung cancer risk assessment.
Lung cancer is a heterogeneous disease and 
researchers have identified vast differences in genomic 
attributes, such as specific variants, gene mutation, gene 
expression and DNA methylation profile, etc., between 
adenocarcinoma (ADE) and squamous cell carcinoma 
(SQC) lung cancer subtype [4, 21-22]. However, the 
knowledge about epistatic features in lung cancer subtypes 
is limited. Performing a stratified epistasis analysis by 
lung cancer histology subtype will provide insights 
concerning tumor-subtype specific genetic interactions 
and gene networks. The availability of large lung cancer 
GWAS data from international collaboration enables 
us to conduct a large-scale epistasis analysis among 
oncogenesis-related genes in overall lung cancer as well 
as lung cancer subtypes. In this study, we collected the 
genotype data from 44,438 individuals with Caucasian 
ancestry, including 20,401 controls and 24,037 cases, 
from three independent cohorts. It is currently the largest 
genetic interaction analysis in lung cancer study to our 
knowledge.
RESULTS
The genotypes from three independent lung cancer 
GWAS including a total of 24,037 lung cancer patients 
and 20,401 health controls with European ancestry 
were collected for the study. Demographic and clinical 
characteristics as well as sample sizes are summarized 
in Table 1. A comprehensive list of 2,027 cancer-related 
genes, including DNA binding proteins, transcription 
factors, transcriptional regulators, and other genes 
regulating protein expression, were identified and used 
to filter the search space for genetic interactions between 
carcinogenesis-related genes (Figure 1A). The study 
strategy is presented in Figure 1B. A stringent Bonferroni 
corrected significance cutoff was calculated based on the 
number of pair-wise tests between independent SNPs and 
p value < 1.95x10-10 was used for significance threshold in 
final meta-analysis.
Discovery study
By use of the “fast-epistasis” option in PLINK to 
quickly screen for interactions, an exhaustive pairwise 
interaction analysis among cancer-related genes was 
conducted in the overall lung cancer cohort (ALL) as 
well as the stratified group by NSCLC, ADE and SQC 
histology subtype using lung cancer OncoArray GWAS 
data in the discovery stage. The sample size in the cohorts 
included 14,260 controls plus 18,401 overall lung cancer 
cases, 13,593 NSCLC cases, 7,157 ADE cases and 4,612 
SQC cases, respectively. In the ALL interaction analysis, 
there were 102, 734, 7113 and 70145 SNP pairs when 
we used p value < 1x10-7, 1x10-6, 1x10-5 and 1x10-4 as 
the significance threshold, respectively. We decided to 
use 1x10-6 as the significance cutoff value to provide a 
balance between including excess false positive results 
versus missing potential signals. There were 717, 917 
Figure 1: Carcinogenesis-related gene selection and statistical analysis strategy used in the study. A. Categorization of the 
molecular functions of the selected 2027 cancer-related genes (DAVID). B. Flow chart of statistical analysis strategy in the study.
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and 1118 SNP pairs with Z-score p value < 1x10-6 from 
NSCLC, ADE and SQC interaction analysis, respectively 
(Appendix 3 Supplementary Table 1). The selected SNP 
pairs were submitted to more stringent logistic regression 
interaction analysis. A total of 678, 673, 883 and 1062 
SNP pairs had logistic interaction p value < 1x10-5 from 
Table 1: Summary and characteristics of three independent GWAS datasets used in the study
OncoArray
N = 32,661
Affymetrix
N = 10,347
GELCC
N = 1,430
Discovery Replication 1 Replication 2
No. Sample Cases  n = 18,401
Controls 
n = 14,260
Cases 
n = 4,950
Controls
n = 5,397 
Cases 
n = 686
Controls
n = 744
Agea 63.8 61.6 62.9 60.4 61.6 64.9
Male (%) 62.5 60.3 53.9 53.4 38.9 35.6
Smoking status 
Never (%) 9.7 32.1 9.7 29.8 13.0 40.1
Former (%) 38.7 39.7 36.2 35.2 87.0c 59.9c
Current (%) 51.6 28.2 54.1 34.9 NA NA
Packyrb 40.7 29.8 28.9 27.6 NA NA
Histology
NSCLC (%) 73.9 63.3 70.8
ADE (%) 38.9 36.4 40.7
SQC (%) 25.1 19.9 14.3
a and b, average statistics for age and packyr (pack year) are provided. c, includes both current and former smokers.
Figure 2: Imputed genetic interaction analysis in candidate regions. 1-4 plots display the results at all lung cancer, NSCLC, 
ADE and SQC cohort, respectively. A. Interaction map with SNPs from ~ 30 kb flanking regions using imputed genotype at discovery 
dataset. The X and Y axis denote the SNPs at each of the gene. The color shade indicates the change of -log10(p) of interaction p value. The 
signals were highlighted in grey-colored boxes. B. Signals from analysis using imputed genotype. The X and Y axis denote location (bp) 
of each of the SNP in one gene and Z axis displayed the -log10(p) from the interaction analysis, the plane in dash line indicated p value of 
1.95x10-10. Black, blue and green color denotes the results from OncoArray, Affymetrix and GELCC imputed genotype data analysis and 
red color denotes the results from joint analysis combining all the datasets.
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ALL, NSCLC, ADE and SQC cohort, respectively. These 
SNP pairs were further submitted to replication study.
Replication study
In the replication study, we first performed logistic 
gene-gene interaction studies for the selected SNP pairs 
in Affymetrix GWAS and GELCC GWAS datasets 
separately and then conducted meta-analysis to combine 
the information from both studies. 37, 50, 33 and 67 SNP 
pairs had a replication meta-analysis p value < 0.05 with 
consistent interaction effects (either risk or protective 
effect) across all three different datasets in ALL, NSCLC, 
ADE and SQC, respectively (Appendix 1). A final meta-
Table 2: Signals from interaction analysis in genotyped discovery data, replication data sets and joint analysis
OncoArray_
genotyped
Affymetrix_
imputed
GELCC_
imputed Joint
SNP1 A1 (MAF) GENE1 SNP2
A1 
(MAF) GENE2 OR P OR P OR P OR P Q
rs74826777 A (0.01) RGL1 rs4902626 A (0.21) RAD51B 0.49 2.83E-07 0.30 9.63E-03 0.22 2.68E-02 0.46
3.24E-
09 0.32
rs74826777 A (0.01) RGL1 rs2877496 A (0.21) RAD51B 0.47 5.20E-08 0.18 6.71E-04 0.24 4.35E-02 0.43
1.59E-
10 0.14
rs74826777 A (0.01) RGL1 rs1474960 G (0.22) RAD51B 0.48 1.39E-07 0.16 3.56E-04 0.20 2.00E-02 0.43
3.11E-
10 0.06
rs74826777 A (0.01) RGL1 rs17835218 A (0.22) RAD51B 0.46 1.14E-08 0.17 4.66E-04 0.34 8.62E-02 0.42
6.60E-
11 0.15
rs74826777 A (0.01) RGL1 rs17835244 C (0.22) RAD51B 0.48 2.89E-08 0.17 4.84E-04 0.29 5.66E-02 0.44
3.27E-
11 0.11
rs3764240 A (0.03) CD109 rs851984 A (0.39) ESR1 1.36 1.63E-06 1.41 9.61E-03 2.08 1.85E-02 1.39
1.01E-
09 0.41
rs3764240 A (0.03) CD109 rs851983 G (0.39) ESR1 1.37 9.29E-07 1.41 9.84E-03 2.08 1.81E-02 1.39
1.01E-
09 0.41
rs3764240 A (0.03) CD109 rs851982 G (0.39) ESR1 1.37 9.86E-07 1.43 7.36E-03 2.08 1.81E-02 1.39
8.30E-
10 0.41
rs7783961 A (0.28) CALCR rs2505532 A (0.41) RET 1.14 4.08E-07 1.10 9.38E-02 1.26 6.03E-02 1.14
8.30E-
07 0.62
NSCLC
rs74826777 A (0.01) RGL1 rs2877496 A (0.21) RAD51B 0.45 1.56E-07 0.16 1.68E-03 0.24 6.20E-02 0.41
3.81E-
10 0.18
rs74826777 A (0.01) RGL1 rs1474960 G (0.22) RAD51B 0.44 7.23E-08 0.13 6.84E-04 0.22 3.92E-02 0.40
9.71E-
11 0.11
rs9677398 A (0.28) THADA rs2648875 A (0.24) PVT1 1.17 4.41E-07 1.11 8.62E-02 1.34 7.20E-02 1.16
9.50E-
09 0.46
rs7570751 G (0.28) THADA rs2648875 A (0.24) PVT1 1.17 3.07E-07 1.11 8.44E-02 1.47 1.87E-02 1.17
5.46E-
09 0.24
rs6544655 G (0.28) THADA rs2648875 A (0.24) PVT1 1.17 6.05E-07 1.11 7.29E-02 1.39 4.36E-02 1.17
4.79E-
09 0.41
rs6544657 G (0.28) THADA rs2648875 A (0.24) PVT1 1.17 2.93E-07 1.11 8.42E-02 1.38 4.56E-02 1.17
7.91E-
09 0.38
rs1554783 G (0.25) SYNE1 rs10515157 A (0.16) RNF43 0.84 1.78E-06 0.81 3.55E-03 0.69 3.70E-02 0.82
1.29E-
08 0.57
ADE
rs2131556 A (0.21) PTPRU rs4646 A (0.27) CYP19A1 0.82 8.54E-07 0.87 8.79E-02 0.64 2.48E-02 0.82
2.70E-
08 0.37
rs1554783 G (0.25) SYNE1 rs10515157 A (0.16) RNF43 0.79 3.04E-07 0.79 8.69E-03 0.52 5.47E-03 0.78
3.18E-
09 0.22
rs2758791 G (0.26) SYNE1 rs10515157 A (0.16) RNF43 0.79 2.31E-07 0.79 8.68E-03 0.58 1.48E-02 0.78
4.28E-
09 0.38
SQC
rs6716971 G (0.06) BRE rs6787614 A (0.12) RUVBL1 1.63 1.12E-06 2.12 2.07E-04 5.30 8.92E-02 1.74
6.03E-
10 0.26
rs1882898 A (0.38) FHIT rs1705235 C (0.05) TSPAN8 1.51 1.45E-07 2.26 2.91E-02 9.95 9.31E-04 1.57
5.95E-
09 0.01
rs11135724 G (0.27) LOXL2 rs208311 G (0.30) P2RX7 0.81 6.63E-07 0.82 3.76E-02 0.58 6.03E-02 0.81
6.31E-
09 0.52
There are 37, 50, 33 and 67 SNP pairs with meta-analysis p value < 0.05 in replication study and only SNP pairs with 
interaction p value < 0.1 in both the two replication datasets are reported in Table 2. OR, p values from each individual dataset 
as well as the joint meta-analysis are reported, and numbers highlighted in red color indicate the overall meta-analysis p values 
< 1.95x10-10 (Bonferroni corrected significance cutoff). 
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analysis was conducted to combine the information from 
both discovery and replication studies at these replicated 
SNP pairs and overall ORs and p values were reported. 
Table 2 displays the results for SNP pairs with logistic 
interaction p value < 1x10-5 in discovery dataset and < 
0.1 from each of the two replication datasets. In ALL 
lung cancer cohort, we identified a significant interaction 
effect between rs74826777, located in gene RGL1, and 
five SNPs located at gene RAD51B. The interaction 
OR varied from 0.46 to 0.49 with p values ranging 
from 1.14x10-8 to 2.83x10-7in discovery study. In the 
replication study, the interaction OR varied from 0.16 to 
0.30 with p values ranging from 3.56x10-4 to 9.63x10-3in 
Affymetrix replication data; and OR varied from 0.20 to 
0.34 with p value ranging from 2.00x10-2 to 8.62x10-2 in 
GELCC replication data. In the overall meta-analysis, 
three SNP pairs had p value < 1.95x10-10 (highlighted 
in red in Table 2). The most significant SNP pair was 
rs74826777:rs17835244 with an overall interaction OR 
of 0.44 and p value of 3.27x10-11. One of the SNP pairs, 
rs74826777:rs1474960, also displayed significant signals 
in NSCLC cohort with OR 0.40 and p value 9.71x10-11 in 
final meta-analysis.
In addition to the significant interaction effect 
detected between RGL1 and RAD51B, we also identified 
some interactions with consistent evidence across 
discovery and replication studies but not achieving 
significance threshold (p value < 1.95x10-10) in the overall 
meta-analysis, such as CD109:ESR1 gene pair in ALL 
cohort, THADA:PVT1 in NSCLC cohort, SYNE1:RNF43 
from ADE cohort, and BRE:RUVBL1 and FHIT:TSPAN8 
from SQC cohort (Table 2). Suggestive evidence for 
genetic interactions between SYNPO2 and BRCA1 gene 
were found in ADE cohort. 8 SNP pairs had significant 
interaction effect in the OncoArray discovery dataset 
and GELCC replication study. However, no supporting 
evidence was identified in Affymetrix replication data 
(Appendix 1). The most significant signal came from 
rs6828669:rs16941 with overall OR of 0.85 and p value 
of 3.95x10-9. 
Imputation analysis in candidate regions
For each unique gene pair reported in Table 2, we 
further imputed the ~30kb flanking regions harboring the 
involved SNPs using the genotypes from the OncoArray 
GWAS data to increase the density of markers in the 
candidate regions. Figure 2A displayed the interaction 
mapping using imputed genotype in discovery data. In 
each plot, X and Y-axis denote the imputed SNPs in each 
of the gene and -log10(p) was represented by shades of 
red color in the heatmap. More potential significant SNPs 
pairs were revealed in the intensive interaction mapping 
and highlighted in grey-colored boxes. For example, 16 
and 25 SNP pairs, between RGL1 and RAD51B gene, 
were found with interaction p value < 1x10-6 in ALL and 
NSCLC discovery cohort, respectively (Appendix 2). 
We further validated the signals in replication datasets 
and performed joint analysis to combine all information. 
Figure 2B displayed the significant signals from the 
imputed genotype analysis. In each plot, X and Y axis 
denoted the location of SNPs at each of the gene and Z 
axis displayed the -log10(p) in the joint meta-analysis, the 
plane in dash line indicated Bonferroni corrected p value 
threshold (1.95x10-10). For the genetic interaction between 
RGL1 and RAD51B gene, we identified 7 and 3 SNP pairs 
with joint p value < 1.95x10-10 from the ALL lung cancer 
and NSCLC cohort, respectively. The most significant 
SNP pair in ALL cohort is rs74826777:rs8006890 
with an OR of 0.39 and p value of 1.68x10-11; and 
rs74826777:rs17835244 with OR 0.38 and p value of 
3.76x10-11 in NSCLC cohort (Figure 2B 1&2, Appendix 
2). The interaction analysis using imputed genotype data 
reinforced the finding for interaction between RGL1 and 
RAD51B gene. 
In the ADE and SQC cohort, we identified some 
evidence for genetic interactions in SYNE1:RNF43 and 
FHIT:TSPAN8 gene pairs in discovery and replication 
study but none of the SNP pairs achieved the significance 
level (Table 2). Fortunately, the intensive interaction 
mapping using imputed genotype provided us strong 
evidence for epistasis between these two gene pairs. In 
ADE subtype, we identified 111 SNP pairs with meta-
analysis p value < 1.95x10-10 coming from 14 SNPs at 
SYNE1 and 8 SNPs at RNF43 gene. The most significant 
interaction came from SNP pair rs12213593:rs11079348 
with OR 0.73 and p value of 1.01x10-12. In SQC cohort, 21 
SNP pairs, coming from 16 SNPs at FHIT and 3 SNPs at 
TSPAN8, had meta-analysis p value < 1.95x10-10. The most 
significant SNP pair was rs1882898:rs1798081 with OR 
0.60 and p value of 7.62x10-11 (Figure 2B 3&4, Appendix 
2). 
Epistasis in lung cancer risk development
In order to investigate how the genetic variation 
at one locus impacted the risk effect at the other locus 
in the identified significant SNP pairs we further 
conducted stratified association analysis. Take the 
rs74826777:rs17835244 pair from RGL1:RAD51B 
gene pair as an example, these two SNPs had p value 
of 0.16 and 0.02 in single-locus association analysis 
in ALL lung cancer cohort, respectively, indicating no 
significant main effect in lung cancer development. In 
the stratified analysis, for individuals with no minor allele 
at rs74826777 (RGL1 gene), rs17835244 (RAD51B) 
does not impact lung cancer risk (p value = 0.51); but 
for individuals with at least one copy of minor alleles 
at rs74826777, rs17835244 displays a protective effect 
for lung cancer with OR 0.46 and p value of 1.22x10-8 
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(Figure 3A). This association of rs17835244 with lung 
cancer is so significant that it achieves a genome-wide 
significance level in a standard GWAS study (p < 5x10-
8). Similar results were detected in RAD51B:RGL1 gene 
pair in NSCLC cohort (Figure 3A). These results present 
a perfect example explaining epistasis contributes to lung 
cancer risk development which cannot be revealed by 
single-locus main effect screening. 
For the RNF43:SYNE1 gene pair identified in ADE 
cohort, rs10515157 slightly increases the ADE risk (OR = 
1.11 and p value = 6.85x10-3) among individuals carrying 
no minor allele at rs1554783; whereas decreases ADE 
risk among individuals carrying at least one minor allele 
at rs1554783 (OR = 0.85 and p value = 1.90x10-4). For 
the FHIT:TSPAN8 gene pair identified in SQC cohort, 
rs1882898, located in FHIT, slightly decreases SQC risk 
among individuals with no minor allele at rs1705235 (OR 
= 0.94 and p value = 2.50x10-2); whereas increases SQC 
risk among individuals with at least one minor allele at 
rs1705235 (OR = 1.41 and p value = 1.48x10-5). These 
results displayed reverse risk effect at one genetic locus 
when the genotype was different at second locus. 
We further analyzed the lung cancer risk effect with 
joint genotypes at the SNP pairs, with no minor allele 
at either locus (0/0) as reference group. For SNP pair 
rs74826777:rs1474960, from RGL1:RAD51B gene pair, 
individuals with genotype 1/0 had a lung cancer risk effect 
with OR 1.31 and p value 0.01 whereas individuals with 
genotype 1/1 had a reduced effect with OR 0.51 and p 
value 6.46x10-7 (Figure 3B-2). Similar effect was obtained 
in all lung cancer cohort (Figure 3B-1). For FHIT:TSPAN8 
gene pair identified from SQC cohort, individuals with 
genotype 0/1 had a significant reduced lung cancer risk 
with OR 0.63 and p value 9.15x10-6 (Figure 3B-4). 
Genetic interactions on gene expression in the 
lung
We further explored the impact of identified genetic 
interactions on the expression of involved cancer-related 
genes using the lung eQTL dataset including a total of 
409 subjects with both genotyping and gene expression 
data [23-24]. We evaluated the interaction effects of 
the significant SNP pairs on gene expression levels. 
For the significant SNP pair rs10515157:rs1554783 
Figure 3: Interaction analysis at candidate gene pairs. A. Stratified lung cancer risk analysis at the identified significant SNP pairs 
using genotype data in discovery OncoArray data. MAF1 and MAF2 indicate the minor allele frequency of each SNP in the pair. 0 and 1 
indicate the genotype without or with at least one copy of minor allele in second SNP. P values and ORs of SNP1 in main effect association 
conditioned on genotype at SNP2 were displayed. B. the bar plots of risk effect at joint genotypes. In each plot, the genotype with no MAF 
at either locus (0/0) was used as reference group. C. Analysis of the genetic interaction effect on gene expression in human lung tissues. 
The interaction effects of SNP pairs on gene expression levels were evaluated using linear models. The evaluated genes and selected probes 
were labeled at Y-axes. The boxplots of gene expression level were plotted for each joint genotype group to display the genetic interaction 
effect on gene expression. Genotypes were coded in a dominant mode, i.e. 0 or 1 for absence or presence of the minor allele, respectively.
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from RNF43:SYNE1 gene pair, SYNE1 gene expression 
levels are significantly different across four groups with 
different joint genotypes (Figure 3C-2, P = 6.82x10-3). 
With a dominant genotype model in both of the SNPs, the 
individuals with 1/0 and 0/1 joint genotype have lower 
SYNE1 expression compared with 0/0 and 1/1 groups. 
Another differentially expressed gene is TSPAN8 from 
SNP pair rs1882898:rs1705235 (Figure 3C-3, P = 4.67x10-
2). We detected decreased gene expression in 1/0, 0/1 and 
1/1 groups compared with 0/0 genotype group. For the 
SNP pair rs17835244:rs74826777 from RGL1:RAD51B 
gene pair, the rs74826777 is not available in the lung 
eQTL dataset and was replaced by the best available proxy 
(rs12733281, D’ = 1, R2 = 0.33 in European population). 
Because the low allele frequency in rs74826777 (and 
proxy rs12733281) (MAF ~ 0.01), we had a limited 
number of samples to test the interaction. We did not 
identify differential gene expression in the gene pairs, but 
we did see a trend of increased expression in 1/1 genotype 
group (Figure 3C-1, P = 0.12). No significant interaction 
signals were found for expression levels of RGL1, RNF43, 
and FHIT (Appendix 3 Supplementary Figure 1). 
Gene set enrichment analysis
The statistical analysis using GWAS data provided 
very significant statistical evidence for genetic interactions 
between selected genes. However, we wanted to further 
explore the underlying biological mechanisms behind the 
statistical findings and understand the genetic architecture 
of epistasis acting more generally. In ALL lung cancer 
cohort, 37 SNP pairs had meta-analysis p value < 0.05 in 
replication analysis and displayed consistent interaction 
effect across three independent datasets. These 37 SNP 
pairs came from 38 unique cancer-related genes and these 
genes were submitted to IPA program for pathway and 
network analysis. Similarly, 43, 36 and 76 genes were 
submitted to IPA program from NSCLC, ADE and SQC 
cohorts, respectively. The top 5 canonical pathways from 
each lung cancer histology subtype are listed in Table 
3 and all of them had a Fisher exact test p value less 
than 0.01 suggesting the input genes were biologically 
connected rather than randomly associated. The pathway 
“hot spot” genes from ALL and NSCLC are EGF, FGFR2, 
EGFR, and GSK3B, etc. The regulation of the epithelial-
mesenchymal transition (EMT) pathway is among the top 
5 canonical pathways in both ALL (p = 1.79x10-5) and 
NSCLC (p = 6.02x10-3) lung cancer cohorts. EMT is an 
evolutionary conserved process which is induced in the 
metastasis process, converting stationary epithelial cells to 
invasive and mobile mesenchymal cells [25-28]. The top 2 
canonical pathways in ADE cohort, both include BRCA1 
and HUS1 gene, are Role of CHK Proteins in Cell Cycle 
Checkpoint Control (p = 1.12x10-4) and DNA damage-
Table 3: Top 5 canonical pathways involving the genes from identified genetic interactions in each lung cancer subtype
Subset Canonical pathways P Overlap 
ALL Glioblastoma Multiforme Signaling (TSC1, EGF, PLCB1, FGFR2, GSK3B, EGFR) 3.35x10-7 6/162
HER-2 signaling (TSC1, EGF, FGFR2, GSK3B, EGFR) 4.18x10-7 5/88
Gαq Signaling (CALCR, NFATC2, PLCB1, FGFR2, GSK3B) 8.24x10-6 5/161
Regulation of the Epithelial-Mesenchymal Transition Pathway (NOTCH4, EGF, FGFR2, GSK3B, EGFR) 1.79x10-5 5/189
ErbB Signaling (EGF, FGFR2, GSK3B, EGFR) 2.46x10-5 4/98
NSCLC Regulation of the Epithelial-Mesenchymal Transition Pathway (BCL9, EGFR, FGFR2) 6.02x10-3 3/189
UVB-Induced MAPK Signaling (EGFR, FGFR2) 7.43x10-3 2/66
EGF Signaling (EGFR, FGFR2) 7.87x10-3 2/68
Caveolar-mediated Endocytosis Signaling (EGFR, ITGA11) 8.55x10-3 2/71
ErbB4 Signaling (FGFR2, YAP1) 8.79x10-3 2/71
ADE Role of CHK Proteins in Cell Cycle Checkpoint Control (BRCA1, E2F2, HUS1) 1.12x10-4 3/57
DNA damage-induced 14-3-3σ Signaling (BRCA1, HUS1) 4.40x10-4 2/19
Glioma Signaling (E2F2, EGFR, IGF2R) 8.60x10-4 3/114
Role of Oct4 in Mammalian Embryonic Stem Cell Pluripotency (BRCA1, POU5F1) 2.59x10-3 2/46
Spliceosomal Cycle (U2AF1/U2AF1L5) 3.28x10-3 1/2
SQC Osteoarthritis Pathway (CASP8, FN1, GLI3, PaRX7, PPARD, SDC4, TCF7L2) 8.84x10-6 7/212
Protein Kinase A Signaling (AKAP12, CDC25C, DUSP10, GLI3, PDE4D, PLCB1, PTPRE, TCF7L2, TGFB2) 1.00x10-5 9/401
Aryl Hydrocarbon Receptor Signaling (ATR, ESR1, ESR2, TGFB2) 1.46x10-3 4/141
Inflammasome Pathway (CASP8, P2RX7) 2.16x10-3 2/20
Molecular Mechanisms of Cancer (ATR, CASP8, CDC25C, GAB2, PLCB1, TGFB2) 2.45x10-3 6/394
Fisher exact test p value is displayed to evaluate if the input genes are biologically connected rather than randomly associated. 
Overlap indicates the number of input genes overlapped with the number of genes in a well-known canonical pathway.
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induced 14-3-3σ Signaling pathway (p = 4.40x10-4). Both 
these two pathways have been reported to be involved in 
lung carcinogenesis and prognosis [29-31]. 
In addition to the already known canonical pathways, 
we are also interested in the de novo gene networks that 
may exist among the interactive genes. Figure 4A-4C 
plots displayed the top putative gene networks curated by 
epistasis-involved candidate genes from NSCLC, ADE 
and SQC subgroup interaction analysis. In each plot, 
red lines indicate genetic interactions either achieving 
the significance level (p < 1.95x10-10) in the joint meta-
analysis; blue lines indicate SNP pairs with consistent 
evidence for genetic interaction across discovery and 
replication data sets but not achieving significance level 
in joint analysis. In NSCLC lung cancer cohort, IPA 
created two top gene networks with RAD51B in one 
network and RGL1 in the other (Figure 4A). Similar gene 
networks results were found in ALL lung cancer cohort 
(Appendix 3 Supplementary Figure 2). The significant 
genetic interactions between SYNE1 and RNF43 in 
the ADE cohort, and between TSPAN8 and FHIT in 
SQC cohort were both demonstrated as interactions 
between two putative networks (Figure 4B-4C). In 
addition to the significant between-network interactions 
in RAD51B:RGL1, SYNE1:RNF43 and TSPAN8:FHIT 
pairs, we also see within-network interactions, such as 
the interaction between THADA and PVT1 in the NSCLC 
cohort, and between BRCA1 and SYNPO2 in ADE cohort, 
etc (Figure 4A-4B). 
DISCUSSION
Epistasis is an important mechanism contributing 
to development of complex human diseases. However, 
new discoveries of genetic interactions derived from 
association analysis have been limited because of the 
challenge in high-dimensional statistical analysis. In 
this paper, we reported a filtered G x G interaction 
analysis among oncogenesis-related genes in lung cancer 
development aiming to identify important oncogene 
or tumor suppressor genes involved in lung cancer 
development by interacting with other modifier genes. 
This study design also has the advantage to reduce the 
search space and thus improve the statistical power in 
epistasis analysis. We collected the GWAS data from 
lung cancer OncoArray Consortium in discovery stage 
and two independent GWAS data sets for replication 
study. A total of 44,438 individuals including 24,037 lung 
cancer patients and 20,401 health controls from European 
descent population were recruited in this study, which is 
by far the largest genetic interaction study in lung cancer 
to our knowledge. We successfully identified epistasis 
in RGL1:RAD51B in ALL and NSCLC lung cancer, 
SYNE1:RNF43 in ADE and FHIT:TSPAN8 in SQC risk 
development. None of the SNPs, from the significant SNP 
pairs, were revealed previously in main effect association 
analysis either from our discovery dataset (P > 0.01) or 
from other published lung cancer GWAS reports. These 
findings reinforce that genetic epistasis among cancer-
related genes is a common mechanism involved in lung 
tumorigenesis and many latent genes contribute to lung 
cancer development through interacting with other 
modifier genes.
We further extended the lung cancer risk analysis 
to lung eQTL gene expression analysis. SYNE1 was 
implicated in many cancers and gene expression 
profiles analysis in TCGA displayed that SYNE1 was 
downregulated in 18 cancer types, including NSCLC, 
breast cancer and colon cancer, etc, compared with normal 
tissues [32]. In the gene expression analysis between 
SYNE1 and rs10515157:rs1554783 SNP pair, the SYNE1 
gene expression were slightly decreased in groups with 
1/0 and 0/1 joint genotype and increased in 1/1 group 
compared with 0/0 reference group (Figure 3C-2). These 
results were consistent with the observed increased lung 
cancer risk in 1/0 and 0/1 group, and decreased risk in 
1/1 group in our epistasis analysis (Figure 3B-3). In the 
study between TSPAN8 gene and rs1882898:rs1705235 
SNP pair, we also identified consistent evidence between 
risk and gene expression analysis. TSPAN8 gene played 
an important role in cancer initiation and overexpression 
was discovered in colorectal, pancreatic and NSCLC, etc 
[33-35]. The decreased expression in joint genotype 1/0 
and 0/1 group were consistent with the decreased lung 
cancer risk in these two groups. RAD51B, as a tumor 
suppressor gene, belongs to RAD51 protein family that is 
essential for DNA repair by homologous recombination. 
Overexpression of RAD51B is found to be associated 
with better prognosis in NSCLC [36-37]. For the 
RAD51B gene, we did not identify interaction signals in 
gene expression analysis because of the limited sample 
size to test low frequency alleles and there were only 6 
individuals with the highest risk joint genotype (Figure 
3C-1). However, we see a trend of increased expression 
in 1/1 group and decreased expression in 0/1 group, which 
supports the decreased risk effect in 1/1 and increased risk 
in 0/1 group, respectively (Figure 3B 1-2). In summary, 
the gene expression analysis provides information about 
the functional role of the identified genetic interactions in 
lung cancer development, supporting the findings of this 
study and yield insights about the molecular mechanisms 
of lung carcinogenesis. 
In the gene network analysis, the IPA program 
constructed gene networks by searching the extensive 
records maintained in its library to find the genes that 
may directly or indirectly connected with the input 
“seeds” from interaction analysis. Interestingly, all the 
three significant epistasis—-RGL1:RAD51B in ALL 
and NSCLC lung cancer, SYNE1:RNF43 in ADE and 
FHIT:TSPAN8 in SQC risk development—-were displayed 
as interaction between networks (Figure 4 and Appendix 
3 Supplementary Figure 2). These results suggest that 
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Figure 4: Gene network analysis using IPA program. A.-C. displayed the top networks from NSCLC, ADE and SQC cohort, 
respectively. Genes labeled with pink color indicate the input candidate genes from interaction analysis. Arrow lines indicate the potential 
genetic interactions identified in G x G analysis. Red lines indicate those genetic interactions either achieving the significance level in 
the joint analysis or having multiple SNP pairs with consistent evidence for genetic interaction across discovery and replication data sets 
although not achieving significance level in joint analysis; blue line indicate sporadic signals for potential genetic interactions without 
achieving significance.
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lung cancer has a very complex molecular mechanism 
and interactions among gene networks, rather than just 
interactions between individual genes, are involved in lung 
cancer development. 
Lung cancer is a heterogeneous disease and different 
genetic variants have been identified associated with 
overall lung cancer risk as well as lung cancer subtypes 
[4,38]. The large sample size in our study and the high 
density of imputed SNP markers allow us to identify lung 
cancer subtype-specific epistasis including RGL1:RAD51B 
in NSCLC (OR = 0.40, p = 9.71x10-11), SYNE1:RNF43 
in ADE cohort (OR = 0.73, p = 1.01x10-12), and 
FHIT:TSPAN8 in SQC cohort (OR = 0.60, p = 7.62x10-
11). The pathway and gene network analysis also display 
the differences in epistasis and signaling pathways in lung 
cancer subtype which enhances our understanding of the 
molecular mechanisms underlying lung cancer subtypes.
Stringent Bonferroni correction, assuming the 
independence among all the tests, was applied to control 
the multiple comparison issue in our study. However, the 
Bonferroni multiple test correction is overly conservative 
for pair-wise interaction analysis. The pair-wise 
interaction tests are positively correlated with each other. 
Our application of the overly conservative Bonferroni 
corrected p value < 1.95x10-10 may have led to our not 
detecting some significant findings. We believe more 
genetic interactions including those with small effects and 
histology subtype-specific effects could be identified in 
the future as more samples with genotype data become 
available. With current knowledge, the information 
about the functional significance of the identified SNPs 
is remains limited in our study, but we were fortunate to 
be able to analyze effects on joint genotypes from a study 
of lung tissues. With the development of the functional 
annotations on the GWAS SNP panel we wish to identify 
genetic interactions with important diagnosis and 
prognosis value in lung cancer disease in the future.
MATERIALS AND METHODS
Study populations
We collected the genotype data from three 
independent lung cancer GWAS including a total 
of 24,037 lung cancer patients and 20,401 health 
controls with Caucasian ancestry in the study. TRICL 
(Transdisciplinary Research In Cancer of the Lung) 
OncoArray consortium GWAS data were analyzed in the 
discovery stage, including 14,260 controls and 18,401 
lung cancer patients (dbGaP Study Accession: phs001273.
v1.p1) (Table 1)4. All the samples were genotyped using 
the Illumina OncoArray-500K BeadChip and 502,933 
SNPs remained for analysis after quality control processes. 
Two independent lung cancer GWAS data were analyzed 
in the replication study: TRICL Affymetrix GWAS 
data including 5,397 controls and 4,950 lung cancer 
cases (http://www.ncbi.nlm.nih.gov/projects/gap/cgi-
bin/study.cgi?study_id=phs000876.v1.p1), and GELCC 
(Genetic Epidemiology of Lung Cancer Consortium) 
familial lung cancer GWAS including 744 controls and 
686 lung cancer patients genotyped using Illumina 
HumanOmniExpressExome-8v1 array [38-39]. The 
demographic and clinical characteristics of each dataset 
including age, gender, and smoking status, histology 
subtypes, etc., were provided in Table 1. IBD analysis was 
conducted between the datasets and duplicated samples 
were removed before the epistasis analysis. 
Ethics statement
All subjects provided informed consent, and the 
institutional review boards of each participating institutes 
approved this collaborative study. Further details about 
the specific studies are provided in prior studies of the 
Oncoarray, TRICL Affymetrix array, and GELCC study 
[4,38-39]. Data from all of these studies have been 
uploaded to dbGAP (phs001273.v1.p1, phs0 phs000878.
v1.p1).
Cancer related genes filtering process
We sought to obtain a list including the oncogenesis-
related gene as complete as possible for this filtered 
epistasis analysis. The Bushman Lab generated a 
comprehensive list of 2,027 cancer-related genes which 
were selected based on information from the Atlas of 
Genetics and Cytogenetics in Oncology and Hematology, 
Catalog of Somatic Mutations in Cancer (COSMIC), and 
the Consensus Coding Sequences of Human Breast and 
Colorectal Cancer, etc [40]. The majority of these genes 
are encoded for DNA binding proteins, transcription 
factors, transcriptional regulators, and other genes 
regulating protein expression (Figure 1A) [41]. The well-
known lung cancer related genes, such as lung tumor 
mutation-harboring genes EGFR, KRAS, BRAF and risk-
associated genes - nicotinic acetylcholine receptor family 
(CHRNB4, CHRNA3, CHRNA5, etc.), CYP gene family 
(CYP1A1, CYP2A6, CYP2D6, etc.), and TERT, etc., are 
also included in these 2,027 genes. The ~500,000 post-
quality control SNPs from the discovery OncoArray 
GWAS data were narrowed down to 43,652 SNPs located 
within transcript region (including untranslated regions) 
of these 2,027 cancer-related genes. We further removed 
SNPs with minor allele frequency (MAF) < 0.005 because 
these variants had little power in genetic interaction 
analysis and the number of SNPs in final analysis was 
35,031. 
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Statistical analysis
Significance p value threshold calculation
Specifying a reasonable Bonferroni corrected p 
value threshold is an important step in analysis of high 
dimensional data. Among the 35,031 tested SNPs, some 
of them are not independent from each other because 
of linkage disequilibrium (LD). We applied the GEC 
(Genetic Type I error calculator) program to evaluate the 
eigenvectors of the correlation matrix and computed the 
number of independent SNPs in the analysis [42]. We 
found there were 22,622 independent SNPs among the 
35,031 tested SNPs and the number of pairwise interaction 
tests was 255,866,131. The Bonferroni corrected p value 
cutoff assuming independence among all the tests was 
computed as 0.05/255,866,131 = 1.95x10-10. Any SNP 
pairs with joint interaction p value < 1.95x10-10 will be 
reported as significant findings. 
Epistasis analysis
In this proposed genetic interaction analysis, we 
followed a two-stage study design: we conducted the 
interaction analysis at discovery stage using OncoArray 
GWAS data, and then replicated the signals using 
independent Affymetrix and GELCC GWAS datasets. A 
two-step analysis strategy was adopted in the discovery 
stage: in step 1, an imprecise but fast pairwise epistasis 
analysis was conducted using the “fast-epistasis” option 
in PLINK program [43]. This test was based on a Z-score 
test to compare the difference of SNP1-SNP2 allelic 
association between cases and controls. SNP pairs with 
p value < 1x10-6 were submitted to a more stringent 
logistic regression analysis using formula (1) at step 2. 
An R program was used for logistic regression interaction 
analysis and the first three principal components (PCs) 
were adjusted in the analysis. In order to harvest as many 
potential signals as possible in discovery study we relaxed 
the significance cutoff to 1x10-5 in regression analysis. The 
SNP pairs with logistic regression interaction p value less 
than 1x10-5 were further submitted to replication studies. 
logit (D) = β0 + β1 × snp1 + β2 × snp2 + β3 × snp1 × snp2 
+ ∑ βi x covi (1)
In the replication study, the same regression model 
specified by formula (1) was applied in the analysis. 
Considering the small sample size in the GELCC GWAS 
dataset (n = 1430) compared with the TRICL Affymetrix 
GWAS (n = 10,347), we performed a meta-analysis in the 
replication study to combine the information from both 
datasets. The SNP pairs with interaction meta-analysis p 
value < 0.05 and consistent interaction effects (OR > or 
< 1 across different discovery and replication datasets) 
were reported as replicated signals. We then performed a 
final meta-analysis to combine the information from all 
three datasets in discovery and replication stage. Figure 
1B displayed the flowchart of research strategy in the 
epistasis study. We applied the same research strategy in 
overall lung cancer cohort as well as stratified analysis by 
lung cancer subtypes NSCLC (non-small cell lung cancer), 
ADE and SQC. 
Genotype imputation
The genotypes from the three GWAS datasets came 
from different platforms and the overlaps among the 
SNP panels were limited. We used IMPUTE2 program 
to impute the genotype in replication datasets to increase 
the SNP overlaps between the discovery and replication 
datasets. For those candidate SNP pairs with meta-analysis 
p value < 0.1 in each replication study we further imputed 
the flanking SNPs in ~30 kb of those candidate SNPs in 
the discovery data to increase the density of SNP markers. 
The 1000 Genomes Project Phase 3 release was used as 
the reference dataset [44]. The output dosage file from 
IMPUTE2 was used as input in logistic regression analysis 
and the first three PCs were adjusted in the imputed 
genotype analysis. 
Genetic interactions on gene expression in the 
lung
Identified epistasis on lung cancer risk were 
extended to gene expression levels using the lung eQTL 
dataset [23-24]. Briefly, lung specimens were collected 
from patients undergoing lung cancer surgery and stored 
at the biobank of the “Institut universitaire de cardiologie 
et de pneumologie de Québec” (IUCPQ). Genotyping was 
carried out using the Illumina Human1M-Duo BeadChip. 
Expression profiling was performed using an Affymetrix 
custom array (see GEO platform GPL10379). A total 
of 409 subjects passed genotyping and gene expression 
quality controls. Expression values were adjusted for age, 
sex and smoking status. Probe sets and SNPs implicated 
in the identified genetic interactions for lung cancer risk 
were selected including RGL1:RAD51B, RNF43:SYNE1, 
and FHIT:TSPAN8. The interaction effects of SNP pairs on 
gene expression levels were evaluated using linear models. 
Genotypes were coded in a dominant mode, i.e. 0 or 1 for 
absence or presence of the minor allele, respectively.
Gene set enrichment analysis
Gene set enrichment analysis provided information 
about the biological implications underlying statistical 
findings in our genetic interaction analysis. We conducted 
canonical pathway and gene network analysis using 
Ingenuity Pathway Analysis (IPA, QIAGEN Inc., https://
www.qiagenbioinformatics.com/products/ingenuity-
Oncotarget1773www.oncotarget.com
pathway-analysis) software to explore the possible 
relationships among the candidate genes. The oncogenesis-
related genes from the SNP pairs with interaction meta-
analysis p value < 0.05 in replication study were provided 
as the focus genes in IPA. IPA searched the extensive 
records maintained in its Ingenuity Pathways Knowledge 
Base (IPKB) and created the canonical pathway based on 
well-known biological and molecular pathways. In gene 
network analysis, the IPA program utilized the provided 
list of focus gene as “seeds” and searched IPKB to find the 
genes that may directly or indirectly connected with the 
“seeds” and then created a gene network. The IPA program 
will also conduct a Fisher exact test to compute the 
probability that the association between a given gene set 
and a given pathway, based on well-established signaling 
and metabolic pathways in IPA library, is due to random 
chance and provide a p value for the test. 
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